AgP, which has a global prevalence of 0.1%12, is characterized by a particular early age of disease onset (<35 years of age), which is why patients with AgP generally do not suffer from late-onset diseases like CAD or diabetes. This evidence concerns the gene ATP5MK and coronary artery disorder.